Evidence map›Paper›PMID 33168903›Full record

ArticleScientific reports2020

Evaluation of pathogen specific urinary peptides in tick-borne illnesses.

Ruben Magni, Raghad Almofee, Sameen Yusuf, Claudius Mueller, Ngoc Vuong, Mahmood Almosuli, Minh Thu Hoang, Katherine Meade, Ish Sethi, Nuha Mohammed and 16 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Characterization ofMicroorganisms · 2026
    Article
  2. Borrelia surface proteins: new horizons in Lyme disease diagnosis.Applied microbiology and biotechnology · 2025
    Review
  3. iScience · 2025
    Article
  4. Article
  5. Article
  6. UrinaryJournal of cellular immunology · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 4 institutions in 2 countries.

Ruben MagniCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Raghad AlmofeeCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Sameen YusufCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Claudius MuellerCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Ngoc VuongCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Mahmood AlmosuliCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Minh Thu HoangCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Katherine MeadeCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Ish SethiCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Nuha MohammedCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Robyn AraujoQueensland University of Technology, Brisbane, Australia.
Teresa Kaza McDonaldCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Paul MarcelliCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Virginia EspinaCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Brianna KimCeres Nanosciences, Manassas, USA.
Anja GarritsenInnatoss, Oss, The Netherlands.
Christine GreenMedical Offices of Christine Green, Mountain View, USA.
Paul RussoCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Weidong ZhouCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Iosif VaismanCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Deborah HoadleyNew England Institute for Lyme Disease and Tick-Borne Illness, Longmeadow, USA.
Robert E MolestinaAmerican Type Culture Collection, Manassas, USA.
Hope McIntyreLyme Hope, LLC, Mt Airy, USA.
Lance A LiottaCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA.
Alessandra LuchiniCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, 20110, USA. aluchini@gmu.edu.
George Mason University · USAmerican Type Culture Collection · USCeres Nanosciences · USQueensland University of Technology · AU

Funding

Novel nanoparticular diagnostics for cerebral toxoplasmosis and Chagas in HIV patients living in Latin AmericaR01AI136722 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GILMAN, ROBERT H · 2018 to 2022
$3.3M
Protein painting identifies therapeutic targets at protein-protein interfacesR33CA206937 · NCI · GEORGE MASON UNIVERSITY · PI LIOTTA, LANCE ALLEN · 2016 to 2018
$1.2M
Nanotrap technology for one step preservation and amplification of cancer biomarkR33CA173359 · NCI · GEORGE MASON UNIVERSITY · PI LIOTTA, LANCE ALLEN · 2012 to 2014
$1.1M
Nanotechnology for One Step Concentration and Preservation of Labile Biomarkers iR21CA137706 · NCI · GEORGE MASON UNIVERSITY · PI LIOTTA, LANCE ALLEN · 2009 to 2010
$530k
High sensitivity multiplex detection of tick borne infection peptidesR21AI138135 · NIAID · GEORGE MASON UNIVERSITY · PI LUCHINI, ALESSANDRA · 2019 to 2020
$503k
Sensitive transrenal Mycobacterium tuberculosis nucleic acid detectionR21AI154295 · NIAID · GEORGE MASON UNIVERSITY · PI LUCHINI, ALESSANDRA · 2020 to 2021
$432k
Bridging adult to pediatric markers of tuberculosis disease severityR21HD097472 · NICHD · GEORGE MASON UNIVERSITY · PI LIOTTA, LANCE ALLEN · 2019 to 2020
$426k
NCI NIH HHS R21 CA137706NCI NIH HHS R33 CA173359NCI NIH HHS R33 CA206937NIAID NIH HHS R01 AI136722NIAID NIH HHS R21 AI138135NIAID NIH HHS R21 AI154295NICHD NIH HHS R21 HD097472NIH HHS R21AI138135NIH HHS R21HD097472
6 · The paper itself

Abstract

Mass spectrometry enhanced by nanotechnology can achieve previously unattainable sensitivity for characterizing urinary pathogen-derived peptides. We utilized mass spectrometry enhanced by affinity hydrogel particles (analytical sensitivity = 2.5 pg/mL) to study tick pathogen-specific proteins shed in the urine of patients with (1) erythema migrans rash and acute symptoms, (2) post treatment Lyme disease syndrome (PTLDS), and (3) clinical suspicion of tick-borne illnesses (TBI). Targeted pathogens were Borrelia, Babesia, Anaplasma, Rickettsia, Ehrlichia, Bartonella, Francisella, Powassan virus, tick-borne encephalitis virus, and Colorado tick fever virus. Specificity was defined by 100% amino acid sequence identity with tick-borne pathogen proteins, evolutionary taxonomic verification for related pathogens, and no identity with human or other organisms. Using a cut off of two pathogen peptides, 9/10 acute Lyme Borreliosis patients resulted positive, while we identified zero false positive in 250 controls. Two or more pathogen peptides were identified in 40% of samples from PTLDS and TBI patients (categories 2 and 3 above, n = 59/148). Collectively, 279 distinct unique tick-borne pathogen derived peptides were identified. The number of pathogen specific peptides was directly correlated with presence or absence of symptoms reported by patients (ordinal regression pseudo-R

Indexed as

TicksAdultAgedAlgorithmsAnimalsBabesia microtiBiomarkersBorreliaErythema Chronicum MigransExanthemaFemaleHumansHydrogelsInfectious Disease MedicineLyme DiseaseMaleBiomarkersHydrogelsPeptides

Identifiers

PMID33168903
PMCPMC7653918
OpenAlexW3105445616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.